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SIGNIFICANCE
Alopecia areata is a form of inflammatory autoimmune di-
sease targeting hair follicles. While alopecia areata is not 
directly a life-threatening disease, recent studies in hu-
mans and mice suggest a potential correlation with higher 
risk of heart disease and stroke. We found increased levels 
of cardiac troponin I in blood plasma from patients with 
alopecia areata. Elevated levels of this factor can indicate 
increased heart tissue damage. The data suggest that the 
development of alopecia areata may involve more systemic 
and debilitating effects beyond the skin. A more compre-
hensive evaluation of alopecia areata patients’ heart health 
is warranted.
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The development of androgenetic alopecia is associa-
ted with a risk of developing cardiovascular diseases, 
but the association of alopecia areata with cardiovas-
cular diseases in humans is largely unexplored. We 
measured the plasma level of two common cardio-
vascular disease markers, cardiac troponin I and C-
reactive protein, in alopecia areata and androgenetic 
alopecia-affected subjects. Also, we investigated the 
possible presence of pro-apoptotic factors in the plas-
ma of hair loss subjects. The mean plasma cardiac tro-
ponin I level was highest in alopecia areata subjects, 
moderately higher in androgenetic alopecia subjects, 
and lowest in subjects without hair loss (p < 0.05). 
Alopecia areata subjects not receiving treatments had 
highest levels of cardiac troponin I (p < 0.05). Alope-
cia areata plasma samples with high cardiac troponin I 
levels also induced significantly higher rates of cardio-
myocyte apoptosis in cell culture assays. The results 
suggest the potential for increased heart remodelling. 
Close monitoring of cardiovascular health in alopecia 
areata subjects, as well as subsets of androgenetic 
alopecia patients, may be appropriate.
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The association of androgenetic alopecia (AGA) with cardiovascular diseases (CVDs) has been explored 
by several research groups (1–6). However, the potential 
for links between CVD and most other forms of hair loss 
has not been actively investigated. Alopecia areata (AA) 
is an inflammatory, cell-mediated autoimmune hair loss 
disease that can be associated with other inflammatory 
and autoimmune diseases such as thyroiditis (7), and 
psoriasis (8). We previously identified a higher level of 
cardiac troponin I (cTnI) in C3H/HeJ mice affected by 
AA (9), possibly as a result of chronic inflammation in 
the skin and hair follicles. While the exact form of cardiac 
anomaly was not identified, AA affected mice presented 
with significantly larger heart mass. 
Chronic inflammatory conditions and autoimmune 
diseases, such as psoriasis, rheumatoid arthritis (RA), 
and systemic lupus erythematosus (SLE), are associated 
with significantly higher risks of CVDs (10–12). Recent 
advances in AA research have revealed disease pathways 
that are shared between other forms of autoimmune di-
sease including psoriasis, SLE, and RA (13). As such, AA 
patients may also share similar risks for other conditions. 
While many affected by RA experience asymptomatic, 
subclinical cardiac involvement, coronary artery disease 
is one of the most common causes of death in RA patients 
(14). It has been suggested that aggressive management 
of inflammation in these patients can reduce the risk for 
CVDs. Potentially, the inflammatory response in AA 
may also affect cardiovascular health following similar 
pathways or mechanisms as seen in RA. 
Releasable molecules such as C-reactive protein (CRP) 
and cTnI have been widely used as biomarkers of cardiac 
infarction and heart failure (15 16). CRP is a strong pre-
dictor of new heart failure, myocardial infarction, stroke, 
cardiovascular cell death and also for new onset of diabe-
tes (16). CRP has also been used as a prognostic marker 
for patients already diagnosed with RA and decreased 
levels of CRP have been used as an indication that a drug 
has beneficial effect (17). Significant elevation of CRP 
has previously been identified in males with AGA (18 
19). Since CRP is a mediator of inflammation as well as 
an indicator of immune response, its altered expression 
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Myocardium expresses cTnI which plays an important 
role in regulating the calcium mediated interaction bet-
ween actin and myosin (20). The plasma level of cTnI 
is greatly increased following myocardial infarction due 
to cardiac cell death and tissue restructuring, making 
it an important marker of cardiomyocyte injury (15). 
However, it can also be elevated in advance of ischemia 
in patients who subsequently suffer heart failure (16). It 
has been shown that cTnI level is elevated in RA patients 
even without the presence of heart failure; indicating 
subclinical myocardial injury (21). In general, subjects 
with common subclinical CVDs usually have greater 
than 0.01 µg/ml of plasma cTnI (22). 
In this study, we investigated the plasma levels of 
cTnI and CRP in patients with AA and AGA compared 
to individuals with no hair loss (NHL). Subsequently, 
we examined the potential for blood plasma from AA 
and AGA patients to have an adverse effect on cultured 
cardiomyocytes.
MATERIALS AND METHODS
Study subject recruitment and blood plasma collection
AA-affected, AGA-affected, and control subjects with NHL were 
recruited with informed consent from the Skin Care Centre, and 
Clinical Research Unit, at Vancouver General Hospital according 
to University of British Columbia Clinical Research Ethics Board 
approved protocols. A questionnaire incorporating National Alope-
cia Areata Foundation guidelines (23) was completed at the time 
of blood collection by the interviewing doctor/nurse for each study 
participant regarding their hair loss and background information. 
The extent of hair loss in male AGA affected subjects was clas-
sified using the Norwood scale, while female AGA subjects were 
classified using the Ludwig scale. None of the study subjects had 
CVDs based on their known medical background. Plasma was 
isolated from whole blood (20 ml) and frozen at –80 °C until 
use. A total of 89 AA subjects, 72 AGA subjects, and 34 subjects 
with NHL before matching for age and sex, were included in the 
study (Table SI1). 
AA subjects ranged from those with less than 25%, patchy hair 
loss to subjects with alopecia totalis (AT) and/or alopecia univer-
salis (AU). Non-AA subjects were screened to exclude those with 
inflammatory hair loss such as cicatricial alopecia and comprised 
individuals with either NHL or androgenetic alopecia (AGA). Sex-
matching was performed by separating the sexes into individual 
groups for AA, AGA and NHL. Age matching was performed by 
grouping age groups into 18–35 years, 36–50 years and > 51 years.
Cardiac troponin I and C-reactive protein ELISA analysis
Human cTn I (Calbiotech, Spring Valley, CA) and Human C-
Reactive Protein (eBioscience, San Diego, CA) standard sandwich 
ELISA assays were used to measure plasma levels of cTnI and 
CRP in the study subjects. Average absorbance optical density 
(OD) of the samples was measured by a spectrophotometer, a 
higher concentration of cTnI or CRP would absorb more light, 
resulting in higher OD. Statistical significance was calculated 
by one-way ANOVA with multiple comparisons using GraphPad 
Prism software (La Jolla, CA). Comparisons between two groups 
were performed with Student’s t-test.
Human primary cardiomyocyte culture
Primary HCMs (Applied Biological Materials Inc, Richmond, BC) 
were cultured in T25 BioCoat Collagen I Coated Vented Flasks 
(BD Bioscience, Mississauga, ON) at 200,000 cells/ml in PriGrow 
I medium (ABM Inc) supplemented with 10% FBS and 100 μg/ml 
Streptomycin with 100 U/ml Penicillin (Invitrogen, Grand Island, 
NY). Half of the culture medium was removed every 3 days and 
replenished with fresh complete medium. HCMs were subcultured 
into 24-well BioCoat Collagen I Coated Plates (BD Bioscience) 
at 60,000 cells/500 µl and rested for 2 days before switching to 
PriGrow medium supplemented with human plasma.
Human primary cardiomyocyte apoptosis assay
Separate cultures with PriGrow medium were supplemented 
with 10% plasma from 3 different AA or AGA subjects identified 
with the highest levels of plasma cTnI, 3 AA or AGA subjects 
with lowest plasma cTnI, and 3 NHL subjects. The cultures with 
human plasma were maintained for 10 days with fresh media 
replenished every 2 days. The positive controls for apoptosis 
were wells with PriGrow media without any serum and RPMI 
1640 (Invitrogen) without any serum. The negative controls 
received FBS-supplemented PriGrow media as above. At the 
end of 10 days, the HCMs were collected after trypsinization for 
flow cytometry.
HCMs were labelled with Annexin V (eBioscience, San Diego, 
CA), and Propidium Iodide (PI) (eBioscience) was added into the 
cell suspensions 15 min before flow cytometry analysis. Flow 
cytometry analysis was performed on a BD FACSCanto II flow 
cytometer (BD Bioscience). Statistical significance was calcula-
ted by one-way ANOVA with multiple comparison followed by 
Fisher’s Least Significant Difference test using GraphPad Prism 
software.
Fig. 1. Alopecia areata (AA) and androgenetic alopecia (AGA). AA subject plasma samples had significantly higher levels of cardiac troponin 
I (cTnI) compared to the control group. Both male and female AA subjects had significantly higher levels of cTnI compared to the control group (a, 
b). The plasma levels of C-reactive protein (CRP) showed similar trend, but statistical significance was not achieved. The comparison was performed 
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Multiplex cytokine array for the expression of inflammatory 
cytokines
We performed a multiplex screening of cytokines in the plasma 
samples used in the apoptosis assay. A Cytokine Human 25-
Plex Panel for Luminex (Invitrogen) was performed following 
manufacturer’s protocols. The plasma cytokine profiles were 
determined by the manufacturer as part of the service. Compari-
son of cytokine expression profiles was expressed as a heat map 
generated by GENE-E (Broad Institute, Cambridge, MA, USA).
RESULTS
Higher plasma level of cardiac troponin I and C-reactive 
protein were detected in patients with alopecia areata
Age and sex-matched AA male and female subjects 
showed significantly higher plasma levels of cTnI (Fig 
1a, b) compared to controls (AGA and NHL subjects). 
Comparison of CRP levels showed similar trends (Fig 
1c, d), but statistical significance was not achieved. 
Higher plasma level of cardiac troponin I were detected 
in younger males
Without correcting for sex and age, males with AA ex-
hibited significantly higher levels of cTnI compared to 
NHL and AGA males (Fig. 2a). Higher levels of cTnI 
were also observed in younger age groups (18–35) for 
both AA and AGA (Fig. 2c). Conversely, the levels of 
CRP showed an overall higher trend in all female groups 
compared to males (Fig. 2b). AA and AGA subjects in 
older age groups revealed higher CRP levels and sig-
nificance was observed in AGA subjects over 50 years 
old (Fig. 2d).
Patients with alopecia areata undergoing treatment have 
lower level of cardiac troponin I
AGA subjects who were receiving treatments (finasteride 
and/or minoxidil) showed no difference in plasma cTnI 
levels compared to the no treatment AGA group (Fig. 3a). 
AA subjects who were receiving treatment had higher 
levels of CRP compared to non-treated AA subjects, 
but the difference was not significant. AGA subjects 
also showed no difference in CRP levels regardless of 
receiving treatment or not (Fig. 3b). However, in AA 
subjects that received diphenylcyclopropenone (DPCP) 
immunotherapy only, the level of cTnI was significantly 
lower compared to subjects not receiving any treatment 
(Fig. 3c). No significant difference was observed in the 
level of CRP with either minoxidil only or DPCP only 
Fig. 2. Alopecia areata (AA) and androgenetic alopecia (AGA). The level of cardiac troponin I (cTnI) was higher in males with AA and 
younger age groups while C-reactive protein (CRP) was higher in females and older age groups. AA affected males had significantly higher 
levels of cTnI compared to males in other subject groups, but not with females within the same group (a). The level of CRP was higher in females from all 
subject groups, and was higher in AA and AGA groups (b). In both AA and AGA groups, the level of cTnI was highest in those who were between the age 
of 18 and 35, but statistical significance was only observed in AGA subjects (c). CRP levels did not show a consistent trend for AA subjects, but increased 
linearly as age increased in AGA patients (d). Statistical significance was determined with one-way ANOVA where * denotes p < 0.05.
Fig. 3. Alopecia areata (AA) and androgenetic alopecia (AGA). AA subjects not currently receiving treatments exhibited higher levels of 
cardiac troponin I (cTnI). AA subjects who were not receiving any treatments for hair loss showed significantly higher levels of cTnI compared to those 
who were receiving treatments (a). However, the release of C-reactive protein (CRP) was not significantly correlated to treatments (b). AA patients who 
received diphenylcyclopropenone (DPCP) showed significantly lower levels of cTnI compared to the no treatment group (c) but highest levels of CRP (d). 
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Fig. 4. Alopecia areata (AA) and androgenetic alopecia (AGA). 
AA subject plasma samples with high levels of cardiac troponin I 
(cTnI) induced apoptosis in primary human cardiomyocytes (HCM) 
compared to samples with low levels of cTnI and AGA groups. AA 
plasma samples with higher levels of cTnI induced significantly higher levels 
of Annexin V expression in primary HCM compared to their low cTnI level 
counterparts (a). Significant difference was also observed between AA 
subjects with high cTnI and AGA and NHL subject groups. AA plasma with 
high cTnI also induced significantly higher PI expression in HCM compared 
to low cTnI (b). Significance was determined using ANOVA followed by 
Fisher’s Least Significant Difference (LSD) test where *denotes p < 0.05.
treatment, albeit the level was highest in subjects who 
received DPCP (Fig. 3d). 
Patient with alopecia areata plasma with high cardiac 
troponin I induced apoptosis of human cardiomyocytes
Cell culture media supplemented with AA subject plasma 
samples with higher levels of cTnI were able to induce 
significantly higher expression of early stage apoptosis 
marker Annexin V, as well as late stage apoptosis marker 
PI, in HCM compared to media supplemented with AA 
subjects’ plasma exhibiting low cTnI levels. No statis-
tically significant increases in apoptosis were observed 
with AGA subject and NHL subject plasma samples 
regardless of cTnI levels (Fig. 4a, b). Media supplemen-
ted with plasma from NHL subjects resulted in close to 
baseline levels of apoptosis in HCM. 
Plasma levels of inflammatory cytokines is independent 
to the level of cardiac troponin I
Most of the cytokines measured by multiplex assay 
showed no significant differences between samples. 
However, several cytokines such as IL-12, IL-13 and 
sIL-2R showed the highest level in AA and AGA patients, 
regardless of whether the subjects had high or low plasma 
cTnI. Other common inflammatory cytokines like IFNα 
and IL-1RA were also elevated in AA and AGA patients 
to a lesser extent.
DISCUSSION
The association between AGA and various CVDs have 
been suggested by multiple epidemiological studies and 
meta-analyses (1-3, 5, 24–27). Several epidemiological 
studies have reported a potential link between hair loss 
and CVDs in males, though these observations were 
made as part of larger studies which may have confoun-
ding factors or missing information (25–27). Subsequent 
meta-analyses were limited by the high variability in the 
way observations were made in different reports, but 
these studies provided valuable first hints of potential 
association (1–3). More recent controlled studies with 
larger cohorts implied associations between early AGA 
onset and CVDs, especially in males with Type III vertex 
hair loss (5). To our knowledge, only one small cohort 
study has focused on female AGA and CVDs (24). 
In our previous study with the C3H/HeJ mouse model 
for AA, we observed enlargement of the heart and heart 
blood vessels, somewhat similar to dilated cardiomyopa-
thy and/or atrial fibrillation (AF). Mice with AA exhibited 
significantly elevated cTnI levels in heart tissue extracts, 
and a trend for elevation in blood plasma, relative to 
littermates with no hair loss (9). We also found expres-
sion of IL18 and IL18r1 limited to the atrial tissues of 
AA mice. In humans, both dilated cardiomyopathy and 
AF are associated with increased cTnI release (28, 29). 
Elevated IL-18 is associated with AF and other CVDs, 
and has been shown to promote significant heart remo-
delling (30, 31).
Arrhythmias, including AF, can develop in the absence 
of overt structural heart disease (32). The presence of AF 
can increase the risk for, and severity of, stroke (33), and 
elevated plasma cTnI levels in AF patients are a prog-
nostic indicator for stroke risk (34). Stroke occurs due 
to a lack of blood supply to the brain and body, and AF 
increases the risk of blood clotting in the atria (30, 35). 
A retrospective study indicated no significant difference 
in AA patients’ risk for myocardial infarction and stroke 
(36). However, a recent study which involved a 3-year 
follow-up of AA patients and non-AA subjects, reported 
a significant increase in the rate of stroke in AA patients 
(37). Unlike psoriasis and RA, any link between AA and 
CVDs is less clear, but the observations of cardiac remo-
delling in the AA mouse model, a small but significant 
increase in cTnI release in AA patients, and a possible 
increased risk of stroke in AA patients, circumstantially 
suggests a relationship.
In sex- and age-matched humans, both male and 
female subjects affected by AA exhibited significantly 
higher plasma cTnI levels on average compared to AGA 
and NHL subjects (Fig. 1). While plasma C-reactive 
protein levels showed similar trends, statistical signifi-
cance was not achieved (Fig. 1b, d). Compared to CRP, 
the level of cTnI has a more direct relationship with 
the heart since it is a specific muscle regulatory protein 
produced by cardiac muscle cells (15, 16). While cTnI 
is a strong predictor for heart failure in advance of myo-
cardial ischemia (16), the levels of cTnI detected here 
for all 3 subject groups were below what is classified as 
positive for clinical heart disease (usually >10 ng/ml) 
(22). Therefore, the results indicate that AA subjects may 
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but in the absence of overt CVDs. Similar observations 
have been made in RA patients where higher cTnI levels 
may be an indication of subclinical cardiac injury (21). 
Normal physiological differences in cTnI production 
between males and females are likely reflected in our 
results. The plasma level of cTnI is higher in the general 
male population even without the presence of CVDs (38), 
though whether this is an indication of higher suscepti-
bility to subsequent CVD development is unknown. 
Young age of AGA onset is known to be associated 
with increased risk of CVDs later in life (2, 5, 6). In a 
study that followed RA patients for 5 years, it was found 
that young adults had the highest CVD risk (39). We 
showed increased plasma cTnI was generally observed 
in younger male populations (18–35) with either AA or 
AGA (Fig. 2c); in addition, male AA patients expressed 
significantly higher amounts of cTnI than AGA and NHL 
males (Fig. 2a). Given the apparent relationship between 
CVD risk and young age at AGA or RA onset in males, 
it may be appropriate to more closely evaluate young 
male AA patients for cardiovascular health.
Our data suggests that treatments for AA may have a 
significant effect on plasma cTnI levels. DPCP is used 
to treat AA by inducing a mild contact dermatitis (40). 
Such inflammation may potentially cause an elevation 
of CRP as was observed here (Fig. 3b,d). In contrast, 
subjects who received DPCP showed relatively lower 
secretion of cTnI (Fig. 3c); suggesting the benefits of 
treating AA may extend beyond hair regrowth. Notably, 
AGA patients receiving finasteride and/or minoxidil did 
not exhibit significant changes in plasma cTnI and CRP 
in our study (Fig. 3c, d).
The CRP levels observed in AGA subjects seemed to 
be dependent on age, and were mostly opposite in trend 
to cTnI levels (Fig. 2d). However, this difference might 
be attributed to the increase of low-grade inflammation 
as age increases (41). Female subjects showed higher 
CRP levels than males (Fig. 2b). It has previously been 
reported that females with AGA have higher levels of 
CRP than females without AGA and AGA males (42). 
Increased CRP levels in AA subjects has previously 
been reported (43) and we observed similar increased 
expression in our cohort (Fig. 1c, d). In psoriasis it has 
been hypothesized that circulating inflammatory cytoki-
nes can promote heart tissue damage and development 
of atherosclerosis (44); CRP production is also stimu-
lated by elevated inflammatory cytokines (45). Similar 
mechanisms may be involved in AA, resulting in a rise 
of plasma CRP. As such, whether CRP can be used as a 
direct indicator of cardiac tissue status in the presence 
of chronic inflammatory diseases is open to question. 
We observed that HCMs cultured with plasma from 
AA subjects exhibiting high cTnI levels increased HCM 
apoptosis (Fig. 4). Our results circumstantially suggest 
that unidentified factors are present in the plasma samp-
les of AA patients with high cTnI levels that can induce 
HCM apoptosis (and consequently release cTnI). The 
trend indicates that AA subjects with high cTnI could 
be at risk of increased cardiac remodelling. However, 
whether there is an association with CVD related risks 
such as hypertension (8, 46) via inflammatory cytokines, 
as observed in psoriasis (44), is unknown. Subjects with 
RA or inflammatory polyarthritis present with elevated 
cTnI and CRP, and these are positively correlated with 
CVD risk (21, 47). It is possible that the severity of 
inflammation in RA may be higher and more systemic 
than observed in AA, resulting in a higher level of harm-
ful inflammatory cytokines. This may explain higher 
incidence of CVD manifestations observed in RA than 
in AA. Additional comparisons showed recent onset of 
AGA was associated with higher cTnI plasma levels, 
but the difference was insignificant in AA (Appendix 
S1; SFig. 1a1). CRP level showed an overall increased 
Fig. 5. Alopecia areata (AA) and androgenetic alopecia (AGA). 
Subjects experiencing hair loss secreted higher levels inflammatory 
cytokines. Plasma samples from AA and AGA subjects with either highest 
or lowest cardiac troponin I (cTnI) levels were compared with subjects with 
no hair loss (NHL). Multiplex analysis of 25 inflammatory cytokines revealed 
overall higher expression of IFNα, IL-13, IL-1RA and IL2R in subjects with 
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trend as the duration of AA and AGA increased, but no 
significant difference was observed (SFig. 1b). We also 
stratify AA patients into groups based on their current 
extent of hair loss and found no clear trend between in 
the levels of cTnI and CRP between those with <25% to 
25–75% and >75% (Appendix S1; SFig. 2 a, b1). This is 
most likely because AA patients may experience spon-
taneous regrowth in one spot but losing hair in another 
spot, resulting in fluctuating levels of the biomarkers 
we tested.
Investigation of cytokine expression in the plasma 
samples from AA, AGA and NHL did not identify a spe-
cific relationship between cytokines and HCM apoptosis. 
The overall levels of IL-12, IL-13 and sIL-2R were 
higher in subjects experiencing hair loss, regardless of 
their plasma cTnI level (Fig. 5). Interestingly, previous 
studies have identified elevation of these cytokines in 
different CVDs (48–50). The activation of lymphocytes 
in AA patients most likely resulted in the elevation of 
these cytokines, however, it is unknown why AGA pa-
tients also had higher cytokine levels (albeit still lower 
than AA subjects). Nevertheless, the result could suggest 
that the levels of cTnI and CRP in hair loss patients may 
be independent of inflammatory cytokine expression.
In conclusion, our results indicate that the develop-
ment of AA may be associated with cardiac remodelling, 
as reflected by higher plasma cTnI levels. The study 
data presented here, together with the previous study in 
the AA mouse model, are consistent with an increased 
risk of cardiac-related complications, though evidence 
to link AA to increased CVD risk or subclinical forms 
of heart disease is still lacking. Our study is limited 
by the small population size as well as the absence 
of comprehensive medical background information. 
However, we have provided some initial evidence that 
heart tissue remodelling may occur at a subclinical 
level in AA subjects. Investigations involving a larger 
population with more comprehensive background 
information will help elucidate the association of AA, 
and AGA, with CVD risk.
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